CHMA - Chiasma: An Interesting Bet Despite The Recent Spike
Chiasma Inc. (CHMA) shares rose over 30% recently, buoyed by favorable results from the Phase 3 clinical trial for its octreotide capsules, conditionally trade-named drug Mycapssa, for the maintenance treatment of adults with acromegaly.
Acromegaly is a hormone disorder that typically develops when a benign tumor of the pituitary gland produces too much growth hormone, and is characterized by enlarged bone growth in the hands, feet and face. If untreated, it can lead to early death. Current treatment options are surgery, radiation therapy, and/or medical treatment in cases where surgery or radiation is